Safety of CpG oligodeoxynucleotides in veterinary species

Antisense Nucleic Acid Drug Dev. 2003;13(3):157-67. doi: 10.1089/108729003768247628.

Abstract

Bacterial DNA and synthetic oligodeoxynucleotides (ODNs) containing unmethylated CpG motifs in particular sequence contexts (CpG ODN) are recognized as a danger signal by the innate immune system of vertebrates. For this reason, CpG ODNs have a potential application as both an adjuvant and nonspecific immune modulator and are currently being evaluated in a number of human and veterinary clinical trials. Given their potent immunostimulatory activity, CpG ODNs could possibly induce adverse reactions. As all adjuvants and immune modulators must be nontoxic to meet safety requirements, it was essential to address the safety aspects of CpG ODNs. The current review summarizes experiments carried out to date to establish the safety of CpG ODNs in animals.

Publication types

  • Comparative Study

MeSH terms

  • Adjuvants, Immunologic / administration & dosage
  • Adjuvants, Immunologic / pharmacology
  • Animals
  • Animals, Domestic / blood
  • Animals, Domestic / immunology*
  • Base Sequence
  • Body Temperature
  • Cattle
  • Cell Division / drug effects
  • Cells, Cultured
  • Drug Evaluation, Preclinical
  • Haptoglobins / metabolism
  • Hemocyanins / administration & dosage
  • Hemocyanins / pharmacology
  • Immune System / immunology*
  • Immunoglobulin G / blood
  • Immunoglobulin G / immunology
  • Injections, Intramuscular
  • Injections, Subcutaneous
  • Leukocytes, Mononuclear / drug effects
  • Leukocytes, Mononuclear / immunology
  • Oligodeoxyribonucleotides / administration & dosage
  • Oligodeoxyribonucleotides / genetics
  • Oligodeoxyribonucleotides / immunology*
  • Oligodeoxyribonucleotides / pharmacology*
  • Species Specificity
  • Time Factors

Substances

  • Adjuvants, Immunologic
  • CPG-oligonucleotide
  • Haptoglobins
  • Immunoglobulin G
  • Oligodeoxyribonucleotides
  • Hemocyanins
  • keyhole-limpet hemocyanin